Table 2 Analyses of the relationship between SPSs and recurrence after BAE based on different statistical models

Model 1

SPSs

Present

3.37 (2.07–5.47)

Absent

Reference

Model 2

SPSs

Present

1.96 (1.11–3.49)

Absent

Reference

Age

–

1.00 (0.98–1.02)

Sex

Female

1.42 (0.79–2.54)

Male

Reference

Duration of hemoptysis

> 6 months

1.54 (0.92–2.57)

≤ 6 months

Reference

Underlying lung disease

Bronchiectasis

0.91 (0.18–4.56)

Tuberculosis sequela

0.99 (0.19–5.03)

Chronic pneumonia

0.47 (0.06–3.74)

Cryptogenic hemoptysis

Reference

Volume of hemoptysis

 ≥ 300 ml/d

1.11 (0.58–2.12)

100–300 ml/d

1.27 (0.75–2.16)

 < 100 ml/d

Reference

Smoking

Present

1.03 (0.56–1.89)

Absent

Reference

Hypertension

Present

0.87 (0.48–1.60)

Absent

Reference

Disease extent (number of affected lobes)

–

1.32 (0.99–1.75)

Presence of pleural thickening

Present

1.04 (0.55–1.97)

Absent

Reference

Lung destruction

Present

1.77 (0.80–3.88)

Absent

Reference

Number of culprit BAs

–

0.89 (0.69–1.14)

Presence of culprit NBSAs

Present

1.58 (0.92–2.71)

Absent

Reference

Embolization materials

Gelatin sponge

2.14 (0.66–6.93)

Microsphere

0.97 (0.45–2.09)

PVA

Reference

Model 3

SPSs

Present

2.29 (1.34–3.92)

Absent

Reference

Duration of hemoptysis

 > 6 months

2.00 (1.24–3.23)

 ≤ 6 months

Reference

Presence of culprit NBSAs

Present

1.79 (1.09–2.92)

Absent

Reference

Model 4

SPSs

Present

2.39 (1.44–3.97)

Absent

Reference

Duration of hemoptysis

 > 6 months

1.78 (1.10–2.88)

 ≤ 6 months

Reference

Disease extent (number of affected lobes)

–

1.30 (1.02–1.64)

Lung destruction

Present

2.07 (1.03–4.18)

Absent

Reference